Leading in Cell and Gene Therapy CDMO
Service
Excellence
Leading in Cell and Gene Therapy CDMO
Innovative
Solutions
scroll down
ENCELL Co. Ltd. offers
contract development and manufacturing (CDMO) services
and contract quality testing (CQT) services
through the operation of globally recognized GMP facilities.
CDMO
The ROCKET Platform represents a multi-product
GMP production technology-based CDMO service.
Through the operation of globally recognized GMP facilities,
ENCELL has enhanced its quality management and capabilities,
thereby establishing the capacity to secure contracts for global products.
CQT Services
Raw materials during the manufacturing process:
IPC, DS/DP, stability testing
At ENCELL Co., Ltd., we conduct comprehensive quality and
characterization testing for all samples generated during
the production process, including raw materials, IPC, and DS/DP.
This allows us to guarantee the highest quality standards for our products.
Our mission is to elevate
the quality of advanced biopharmaceuticals through
the application of cutting-edge technology and expertise.
Research Center
CDMO and Contract Quality Services for Cell and Gene Therapies
Our research center is a leading provider of contract research
and quality assurance services for cell and gene therapies.
We specialize in GMP production processes and quality analysis development,
as well as cell characterization and mechanism studies.
Platform Technology
Our platform technology leverages next-generation
stem cell technology to achieve high yields and efficacy.
ENCELL's innovative platform technology addresses key challenges
in cell aging, efficacy, and high-yield production,
offering a cost-effective solution to enhance productivity and profitability.
Pipeline
The Pipeline Overview demonstrates
ENCELL's technological capabilities.
Our company is committed to developing cutting-edge therapeutic products,
including next-generation stem cell therapies, cancer immunotherapy cell treatments,
and AAV-based gene therapies.
Company Information
Cell Therapies and ENCell Forge Strategic APAC Partnership to Advance Cell and Gene Therapy Manufacturing
Melbourne, Australia & Seoul, Republic of Korea — November 05, 2025 — Cell Therapies Pty Ltd (“Cell Therapies”), Australia’s leading cell and gene therapy (CGT) CDMO, and ENCell Co., Ltd. (“ENCell”), a Korea-based advanced biopharmaceutical CDMO, today announced the signing of a Memorandum of Understanding (MOU) aimed at expanding access to CGT development and manufacturing across the Asia-Pacific (APAC) region. The partnership brings together the companies’ world-class GMP manufacturing facilities, technical and regulatory expertise, and extensive regional networks to accelerate the development and delivery of next-generation cell and gene therapies for patients across Asia-Pacific. Strategic Focus Areas Under the MOU, the companies will collaborate across four core areas that are critical to strengthening APAC’s CGT ecosystem: 1. Enhancing CGT Manufacturing and Process Development Cell Therapies and ENCell will jointly optimize and scale manufacturing processes for a broad portfolio of advanced therapies, including MSC, CAR-T, CAR-NK, and iPSC-derived cell therapies. Collaboration includes shared use of GMP-certified facilities for global clinical and commercial supply and co-development of next-generation iPSC-based manufacturing platforms and decentralized production models. 2. Regulatory Alignment and Quality Harmonization The partners will align regulatory strategies across Korea, Australia, Japan, and broader APAC jurisdictions. This includes co-preparation of manufacturing-related regulatory documents and sharing technical and quality expertise to support efficient regional and global submissions. 3. Joint Market Engagement and APAC Expansion The companies plan to conduct joint business development activities targeting regional biotech and pharmaceutical firms, deepen partnerships with hospitals and research institutions, and build a trusted multi-site CGT manufacturing network capable of supporting global clients. 4. Workforce Development and Research Innovation To support the rapid growth of CGT in APAC, Cell Therapies and ENCell will co-develop training programs to strengthen the talent pipeline and jointly pursue research initiatives in next-generation technologies such as allogeneic therapies, iPSC platforms, high-efficiency manufacturing systems, and sustainability-oriented production strategies. The collaboration will also explore cost-of-goods (COGS) optimization to improve long-term manufacturing efficiency. Statements from Company Leaders Dr. Bev Menner, CEO of Cell Therapies, emphasized the importance of the partnership:“This collaboration represents a significant step toward enhancing patient access to innovative cell and gene therapies across the Asia-Pacific region. By working closely with ENCell, we aim to strengthen technical exchange, enhance manufacturing capacity, and establish a robust supply network to support the next generation of advanced therapies.” Dr. Jong Wook Chang, CEO of ENCell, expressed confidence in the partnership’s value:“ENCell fully supports Cell Therapies’ vision to expand the CGT ecosystem throughout the APAC region. By combining the expertise and manufacturing capabilities of both companies, we expect to establish a high-quality CGT production platform connecting Korea and Australia. ENCell will continue to collaborate with global partners to deliver optimal CDMO services that support successful clinical trials and commercialization for our clients.” Advancing APAC’s CGT Ecosystem This MOU is recognized as a model of meaningful cross-border collaboration, supporting the rapid expansion of the CGT industry in the APAC region. By leveraging each country's strengths and shared scientific capabilities, Cell Therapies and ENCell aim to enable regional biotech and pharmaceutical companies to advance their clinical and commercial pipelines with enhanced speed and reliability through a trusted CGT CDMO network. The companies intend to progress to a definitive agreement within the next two to three months and will immediately begin identifying joint project opportunities and executing technical collaboration initiatives.
.jpg)
ENCell Co., Ltd. Selected for the 2020 Seoul Business Agency Bio-Medical Technology Commercialization Support Program
ENCell Co., Ltd. has been selected as a final participant in the 2020 Seoul Business Agency Bio-Medical Technology Commercialization Support Program. The selected project is titled "Development of a Treatment for Duchenne Muscular Dystrophy Utilizing High-Potency/High-Efficiency GMP Technology for Large-Scale Expansion of Early-Passage Umbilical Cord-Derived Mesenchymal Stem Cells." ENCell Co., Ltd. will serve as the lead organization (Project Manager: CEO Jongwook Jang), with Samsung Medical Center participating as a collaborating institution (Division Manager: Professor Jihoon Lee, Department of Pediatrics).Through this project, ENCell aims to accelerate clinical trials and commercialization of its stem cell-based treatment for Duchenne Muscular Dystrophy. By securing funding support from Seoul City, the company is committed to contributing to the growth of Seoul’s bio-medical industry and pledges to dedicate itself to the development of therapies for the rare disease Duchenne Muscular Dystrophy.